Key Highlights

● Recursion rose alongside Schrodinger and Absci.

● No company-specific announcement was found to explain the gain.

● The rally spread to genomics and biotech tools names.

● Rising Treasury yields usually weigh on speculative biotech.

Recursion Pharmaceuticals (NASDAQ:RXRX) climbed as stocks tied to AI-driven drug discovery moved higher together. The stock rose solidly in intraday trading alongside Schrodinger and Absci, with no company news found to explain any of the three moves.

Recursion is one of the most prominent names in AI drug discovery, so it often trades in line with the broader theme.

Moving With the Pack

On this day the rally reached beyond the core group, with Twist Bioscience, Tempus AI and 10x Genomics also rising without fresh news, pointing to a broad wave of buying across biotech tools and data-driven drug research.

Recursion uses automation, machine learning and large biological datasets to search for new medicines, running vast numbers of lab experiments and looking for patterns that might point to promising candidates.

A Narrow Market Backdrop

The Federal Reserve left its benchmark rate range unchanged, with two officials dissenting in favor of a hike, and long-dated Treasury yields climbed, a dynamic that typically pressures companies whose expected profits lie far in the future.

Market breadth was narrow overall, a sign that gains were concentrated in a limited set of stocks even on a day the broader market advanced.